News

Healthcare Asia Magazine on MSN22h
7MM triple-negative breast cancer market eyes 4.7% CAGR growth until 2034
The sector’s expansion is attributed to rising incidence rates. The triple-negative breast cancer (TNBC) market across the ...
DelveInsight Business Research, LLP: Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...
Zacks.com on MSN2d
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...
PharmExec1d
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital
The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...
Zacks Investment Research on MSN6d
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...
Investing Snacks5d
Buy, Sell, or Hold: What’s Next for Bristol Myers?
Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...
Wall Street Journal2d
David V. Elkins - BMY | Bristol Myers Squibb Co. - Wall Street Journal
David V. Elkins currently works at Tapestry, Inc., as Independent Director from 2024 and Bristol Myers Squibb Co., as Chief Financial Officer & Executive Vice President. Mr. Elkins also formerly ...